Tesamorelin

Buy Tesamorelin Online

Tesamorelin is a synthetic growth-hormone-releasing hormone analogue researched particularly for visceral fat reduction, body composition, and metabolic health.

Product Information

Tesamorelin stimulates endogenous growth hormone secretion and has been extensively investigated for its effects on visceral adipose tissue. Human clinical studies have demonstrated reductions in visceral fat in specific patient populations.

How It Works

Tesamorelin mimics GHRH and stimulates the pituitary to increase growth hormone secretion. This downstream GH/IGF-1 signaling can influence fat metabolism and body composition, particularly visceral adipose tissue.

POTENTIAL BENEFITS

1. Visceral-Fat Research

Tesamorelin has demonstrated a measurable ability to reduce visceral adipose tissue in randomized clinical studies, making this its strongest area of human research.

2. Abdominal-Fat Research

Clinical trials have specifically examined tesamorelin in people with excess abdominal fat and found significant reductions in visceral fat compared with placebo.

3. Liver-Fat Research

Research has also reported reductions in liver fat alongside reductions in visceral adipose tissue, giving tesamorelin broader metabolic research interest.

4. Body-Composition Research

By increasing endogenous GH signaling, tesamorelin has been investigated for its ability to shift body-composition parameters and reduce excess visceral adiposity.

5. Metabolic Research

Tesamorelin has also been studied in relation to glucose, triglycerides, and other metabolic markers associated with visceral adiposity.

Dosage

Human clinical trials have commonly used 2 mg subcutaneously once daily. This dose was used in multiple randomized studies examining visceral adipose tissue.

Side Effects

Reported effects include injection-site reactions, joint pain, swelling/fluid retention, headache, and changes in glucose metabolism.

References

• Stanley TL, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation. Journal of Clinical Endocrinology & Metabolism. 2014. PMID: 25038357. PubMed
• Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV-infected patients with abdominal obesity. PubMed. PMID: 28832410. PubMed
• Tesamorelin for the treatment of excess abdominal fat in HIV-1-infected patients. PubMed. PubMed

Note: BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.

Please click here to access instructions on how to make a payment.

How to Pay